Periodic Reporting for period 1 - SenolT (Fast and effective diagnostic test for the early detection of residual tumours to prevent cancer recurrence)
Reporting period: 2018-08-01 to 2019-01-31
Senolytic Therapeutics is a pharmaceutical company that develops a novel class of medicines by targeting damaged cells. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families. The initial target market of SenolT will be cancer patients that received chemotherapy/radiotherapy. It is important for society because we have developed a detection of senescent cells as a diagnostic method to predict recurrence and no other companies are working on that, our competitors are focused on liquid biopsy tests and cancer-related protein markers.
The objectives were:
- Demonstration of the market viability, quantifying the level of market demand and willingness to pay by main users.
- Analysis of the risks and potential entry barriers due to acceptance and regulation.
- Updating of the business plan, plotting the business model, route to market, penetration and marketing strategies, inception and commercialization for SenolT.
- Market survey in 8 countries that has helped assess the potential level of market penetration of SenolT. Finally, we have performed a cost-benefit analysis on the investment needed to produce and sell SenolT with our own manufacturing and sale forces.
- Coordination: We involved all the key personnel participating in the launch of SenolT into the market.
- Business plan: We have drafted a comprehensive Business plan to identify the key countries for the early commercialization of SenolT and consider all appropriate marketing and commercialization strategies.